Biodesix Inc (BDSX)

Currency in USD
14.940
+3.670(+32.56%)
Closed·
14.930-0.010(-0.07%)
·
Unusual trading volume
BDSX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
13.32015.510
52 wk Range
3.43620.210
Key Statistics
Prev. Close
11.27
Open
13.5
Day's Range
13.32-15.51
52 wk Range
3.436-20.21
Volume
448.99K
Average Volume (3m)
108.9K
1-Year Change
53.4894%
Book Value / Share
-0.31
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
BDSX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
30.000
Upside
+100.80%
Members' Sentiments
Bearish
Bullish
ProTips
Significant return over the last week

Biodesix Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Analyst Ratings

5 Buy
0 Hold
0 Sell
Ratings:
5 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 30.000
(+100.80% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Canaccord
Buy22.00+47.26%20.00MaintainMay 05, 2026
Canaccord
Buy20.00+33.87%-MaintainMar 02, 2026
William Blair
Buy---UpgradeFeb 27, 2026
Canaccord Genuity
Buy20.00+33.87%-MaintainJan 13, 2026
Canaccord Genuity
Buy20.00+33.87%-MaintainNov 04, 2025

Biodesix Inc Earnings Call Summary for Q1/2026

  • Biodesix reported Q1 2026 revenue of $25.6M, up 42% YoY; raised full-year guidance to $108M-$114M from previous estimates.
  • Diagnostic testing revenue grew 37% to $22.3M while development services nearly doubled to $3.3M; gross margins improved to 84%.
  • Net loss narrowed 30% to $7.8M despite 18% increase in operating expenses; company continues progress toward profitability.
  • CEO Scott Hutton emphasized expansion of primary care channel and pulmonologist relationships as key growth drivers for 2026.
  • Stock rose 0.27% to $11.11 in after-hours trading; analysts set price targets between $20-$40, suggesting significant upside potential.
Last Updated: 2026-05-04, 05:12 p/m
Read Full Transcript

Earnings

Latest Release
Feb 26, 2026
EPS / Forecast
-0.49 / -0.04
Revenue / Forecast
28.76M / 24.54M
EPS Revisions
Last 90 days

BDSX Income Statement

Compare BDSX to Peers and Sector

Metrics to compare
BDSX
Peers
Sector
Relationship
P/E Ratio
−3.2x7.9x−0.5x
PEG Ratio
−0.11−0.320.00
Price/Book
−46.2x2.7x2.6x
Price / LTM Sales
1.3x4.0x3.3x
Upside (Analyst Target)
166.2%44.8%47.1%
Fair Value Upside
Unlock20.7%6.2%Unlock

Biodesix, Inc. operates as a diagnostic solutions company. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests markets as Nodify Lung Nodule Risk Assessment testing to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR, GeneStrat NGS, and VeriStrat tests markets as part of IQLung testing strategy, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient’s immune system to guide treatment decisions. In addition, the company provides diagnostic solutions, including translational research, initial biomarker discovery, assay design, development and validation, testing of clinical trial samples, regulatory, reimbursement, commercialization, and logistical support services for biopharmaceutical, life sciences, and diagnostic companies. Further, it operates laboratories. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Louisville, Colorado.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
584.83K5.79%6.59M
Other Institutional Investors
3.83M37.94%43.22M
Public Companies & Retail Investors
5.69M56.27%64.10M
Total
10.11M100.00%113.91M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Aigh Capital Management, LLC7.50%758,3288,546
Soleus Capital Management, L.P.4.95%500,0005,635

People Also Watch

50.55
ATEX
+4.49%
16.68
BIOA
+0.36%
8.890
GEOS
-2.95%
62.89
KRMN
-3.72%
10.96
ANGO
-0.18%

FAQ

What Is the Biodesix (BDSX) Stock Price Today?

The Biodesix stock price today is 14.940 USD.

What Stock Exchange Does Biodesix Trade On?

Biodesix is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Biodesix?

The stock symbol for Biodesix is "BDSX."

What Is the Biodesix Market Cap?

As of today, Biodesix market cap is 152.060M USD.

What Is Biodesix's Earnings Per Share (TTM)?

The Biodesix EPS (TTM) is -4.670.

When Is the Next Biodesix Earnings Date?

Biodesix will release its next earnings report on Nov 03, 2025.

From a Technical Analysis Perspective, Is BDSX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Biodesix Stock Split?

Biodesix has split 1 times.

How Many Employees Does Biodesix Have?

Biodesix has 334 employees.

What is the current trading status of Biodesix (BDSX)?

As of May 05, 2026, Biodesix (BDSX) is trading at a price of 14.940 USD, with a previous close of 11.270 USD. The stock has fluctuated within a day range of 13.320 USD to 15.510 USD, while its 52-week range spans from 3.436 USD to 20.210 USD.

What Is Biodesix (BDSX) Price Target According to Analysts?

The average 12-month price target for Biodesix is 30.000 USD, with a high estimate of 40 USD and a low estimate of 20 USD. 5 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +100.80% Upside potential.

What Is the BDSX Premarket Price?

BDSX's last pre-market stock price is 12.960 USD. The pre-market share volume is 21,730.000, and the stock has decreased by 1.690, or 15.000%.

What Is the BDSX After Hours Price?

BDSX's last after hours stock price is 14.930 USD, the stock has decreased by -0.010, or -0.070%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.